The Lancet confirms effectiveness of AZ/Oxford University's COVID-19 vaccine
The Lancet has published peer-reviewed results from an interim analysis of AstraZeneca (AZ) and Oxford University’s phase 3 COVID-19 vaccine programme, confirming the vaccine to be 70.4% effective based on two dosing regimens.
The interim analysis for efficacy of the vaccine, AZD1222, was based on 11,636 participants with 131 symptomatic COVID-19 infections from the phase 3 UK and Brazil trials conducted by Oxford University.
AZ initially announced the interim analysis data in November, revealing that the vaccine candidate had an average efficacy rate of 70% based on two dosing regimens.
The new Lancet data sheds some more light on the exact efficacy for AZ/Oxford’s vaccine programme, demonstrating that AZD1222 is 70.4% effective in preventing symptomatic COVID-19, 14 days after receiving two doses of AZD1222.
Read more: http://www.pmlive.com/pharma_news/the_lancet_confirms_effectiveness_of_azoxford_universitys_covid-19_vaccine_1359763
The interim analysis for efficacy of the vaccine, AZD1222, was based on 11,636 participants with 131 symptomatic COVID-19 infections from the phase 3 UK and Brazil trials conducted by Oxford University.
AZ initially announced the interim analysis data in November, revealing that the vaccine candidate had an average efficacy rate of 70% based on two dosing regimens.
The new Lancet data sheds some more light on the exact efficacy for AZ/Oxford’s vaccine programme, demonstrating that AZD1222 is 70.4% effective in preventing symptomatic COVID-19, 14 days after receiving two doses of AZD1222.
Read more: http://www.pmlive.com/pharma_news/the_lancet_confirms_effectiveness_of_azoxford_universitys_covid-19_vaccine_1359763
